Zentera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapeutics that target critical biological pathways involved in cancer. Their lead compound, Azenosertib, is a first-in-class WEE1 inhibitor designed to induce cancer cell death by preventing the repair of damaged DNA, thereby pushing these cells into mitosis. This innovative approach is particularly relevant for treating various gynecologic malignancies, including platinum-sensitive and resistant ovarian cancers, as well as other solid tumors. Azenosertib is currently undergoing multiple clinical trials, including monotherapy studies and combination therapies with traditional chemotherapy and targeted agents, showcasing its potential in addressing significant unmet medical needs in oncology.

Zentera employs an Integrated Discovery Engine that streamlines the process of identifying and developing novel oncology therapies. This comprehensive approach encompasses the assessment of cancer biology, medicinal chemistry, and the evaluation of chemical scaffolds to create differentiated product candidates. By focusing on clinically validated targets and leveraging their expertise in drug design, Zentera aims to generate strong preclinical data that supports the efficacy and safety of their compounds. This method has enabled the company to successfully advance multiple investigational new drug (IND) applications with the FDA, underscoring their commitment to improving patient outcomes in cancer treatment.

United States

Launched by Zentalis in 2020. Zentera Therapeutics is focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer.

Zentera Therapeutics

Company Details